Predictive value of abnormal expression of MPHOSPH9 in reintervention after high intensity focused ultrasound treatment of uterine fibroids

Aims: Aberrantly expressed MPHOSPH9 has been reported to be associated with poor prognosis in many diseases. Previous study indicates that MPHOSPH9 is abnormally expressed in patients with uterine fibroids (UFs). This study focused on the possible prognostic value of MPHOSPH9 in UFs patients after high intensity focused ultrasound (HIFU) treatment.

Methods: A total of 455 UFs patients participated in the study, including 95 patients who needed reintervention (Reintervention group) and 360 patients who did not need reintervention (Non-reintervention group) after HIFU treatment. They volunteered blood samples before HIFU treatment. The relative expression of MPHOSPH9 was assessed by qRT-PCR. Cox regression analysis was performed to assess the prognostic value of MPHOSPH9 and risk factors of postoperative reintervention.

Results: The expression of MPHOSPH9 was markedly elevated in Reintervention, compared to that of the Non-reintervention group (p < 0.001). Five-year follow-up results showed that among these postoperative patients, 95 patients required reintervention and the reintervention time mainly occurred during 10-40 months after surgery. The Cox regression analysis demonstrated that UFs size (hazard ratio = 2.769, 95% confidence interval: 1.366-5.610) and the high MPHOSPH9 expression level (hazard ratio = 3.160, 95% confidence interval: 1.506-6.630) were independent risk factors for postoperative reintervention.

Conclusions: The enhanced MPHOSPH9 was a potential candidate for predicting postoperative reintervention in UFs patients.